Sign In
Buy ACXP
$1.75
-0.0500 (-2.78%)
At Close: Jun 03, 2026
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
11:43am, Wednesday, 13'th Nov 2024
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO,
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update
07:00am, Wednesday, 13'th Nov 2024
STATEN ISLAND, N.Y. , Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of anti
Acurx Ready To Expand Pipeline With Anthrax Treatment
10:07am, Monday, 21'st Oct 2024
Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat, targeting C. difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 tri
The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatme
STATEN ISLAND, N.Y. , Oct. 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibioti
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
08:00am, Wednesday, 16'th Oct 2024
STATEN ISLAND, N.Y. , Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics
The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign. NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST
10:50am, Friday, 11'th Oct 2024
Featuring ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week NEW YORK, NY / ACCESSWIRE / October 11, 2024 / New to The Street, the leading platform for showc
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
07:00am, Thursday, 26'th Sep 2024
New analyses extend data on beneficial effects of ibezapolstat on the gut microbiome Confirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic concentrations S
Results feature high-resolution elucidation of interaction of ibezapolstat with its molecular target Mechanistic findings explain ibezapolstat's properties of lacking cross resistance with other antib
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
07:00am, Monday, 26'th Aug 2024
September 9-11, 2024 STATEN ISLAND, N.Y. , Aug. 26, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), today announced it will be featured as a presenting company at the H.C.
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
07:01am, Friday, 09'th Aug 2024
STATEN ISLAND, N.Y. , Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of an
STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molec
STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
07:00am, Monday, 15'th Jul 2024
Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative proportion of Actinobacteria in ibezapolstat-treat
